Literature DB >> 15325394

Development of mucosal immunity in the first year of life and relationship to sudden infant death syndrome.

Maree Gleeson1, Allan W Cripps.   

Abstract

The common mucosal immune system (CMIS) is an interconnecting network of immune structures that provides effective immunity to mucosal surfaces. The structures of the mucosal immune system are fully developed in utero by 28 weeks gestation, but in the absence of intrauterine infection, activation does not occur until after birth. Mucosal immune responses occur rapidly in the first weeks of life in response to extensive antigenic exposure. Maturation of the mucosal immune system and establishment of protective immunity varies between individuals but is usually fully developed in the first year of life, irrespective of gestational age at birth. In addition to exposure to pathogenic and commensal bacteria, the major modifier of the developmental patterns in the neonatal period is infant feeding practices. A period of heightened immune responses occurs during the maturation process, particularly between 1 and 6 months, which coincides with the age range during which most cases of sudden infant death syndrome (SIDS) occur. A hyper-immune mucosal response has been a common finding in infants whose death is classified as SIDS, particularly if in association with a prior upper respiratory infection. Inappropriate mucosal immune responses to an otherwise innocuous common antigen and the resulting inflammatory processes have been proposed as factors contributing to SIDS.

Entities:  

Mesh:

Year:  2004        PMID: 15325394     DOI: 10.1016/j.femsim.2004.06.012

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  15 in total

1.  Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors.

Authors:  Gabriel Vinderola; Chantal Matar; Gabriela Perdigon
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Immune exclusion by naturally acquired secretory IgA against pneumococcal pilus-1.

Authors:  Ulrike Binsker; John A Lees; Alexandria J Hammond; Jeffrey N Weiser
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 3.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

4.  Developmental profiles of mucosal immunity in pre-school children.

Authors:  Patricia Ewing; Diana C Otczyk; Stefano Occhipinti; Jennelle M Kyd; Maree Gleeson; Allan W Cripps
Journal:  Clin Dev Immunol       Date:  2010-12-27

5.  Development of mucosal immunity in children: a rationale for sublingual immunotherapy?

Authors:  Aleksandra Szczawinska-Poplonyk
Journal:  J Allergy (Cairo)       Date:  2011-10-27

Review 6.  Animal models for assessment of infection and inflammation: contributions to elucidating the pathophysiology of sudden infant death syndrome.

Authors:  Jane Blood-Siegfried
Journal:  Front Immunol       Date:  2015-03-30       Impact factor: 7.561

Review 7.  Postnatal Innate Immune Development: From Birth to Adulthood.

Authors:  Anastasia Georgountzou; Nikolaos G Papadopoulos
Journal:  Front Immunol       Date:  2017-08-11       Impact factor: 7.561

8.  Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study.

Authors:  Katsunori Tanaka; Takamitsu Tsukahara; Takahide Yanagi; Sayuri Nakahara; Ouki Furukawa; Hidemi Tsutsui; Shigeki Koshida
Journal:  Nutrients       Date:  2017-02-26       Impact factor: 5.717

Review 9.  Cytokines and Soluble Receptors in Breast Milk as Enhancers of Oral Tolerance Development.

Authors:  Bassel Dawod; Jean S Marshall
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

Review 10.  The link between bronchiolitis and asthma.

Authors:  Tuomas Jartti; Mika J Mäkelä; Timo Vanto; Olli Ruuskanen
Journal:  Infect Dis Clin North Am       Date:  2005-09       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.